When: Active Now

Where: Be Well Clinical Studies

Location: Lincoln, Nebraska

To Qualify:

  • Age: 18 to 79

  • Have been on Wegovy at 1.7mg or 2.4mg or Zepbound at 10mg or 15mg for weight loss at stable dose for at least 3 months

  • Are responding well and tolerating the semaglutide or tirzepatide treatment

  • In generally stable health

Reimbursement up to $5,000 is available for study related time and travel.

 

Weight Loss Clinical Trial for Wegovy and Zepbound Users

Be Well Clinical Studies is conducting a clinical research study for weight management and seeing positive results.

Qualified participants will receive all study-related care and investigational medication at no cost. Participants can also receive reimbursement for gym memberships during the study, nutritional counseling and daily meal delivery at no cost.

Volunteer